|
|
|
* - may be subscription-only |
|
|
- Addgene: Expands Viral Vector Service With Packaged
on Request More
- Alkeus Pharmaceuticals: New Positive Interim TEASE-3
Study Results Showing Gildeuretinol Prevented Disease
Progression in Early-Stage Stargardt Patients More
- Alloy Therapeutics: New Licensing Model for ATX-Gx
Antibody Discovery Platform and Launches mAbForge
High-Throughput Screening Service More
- Anumana: Appoints Dr. Simos Kedikoglou as
President and Chief Operating Officer More
- Apellis: Keli Walbert to Join the Board of Directors
More
- BARDA and Partner Therapeutics: Continue Partnership
Around Development of Leukine (sargramostim, rhu
GM-CSF) to Potentially Improve Patient Care for Sepsis
More
- BPGbio: Lipidomics Expertise Powers Groundbreaking
Discovery of Lipid-Rich Cartilage Published in Science
More
- Dyne Therapeutics: New Clinical Data Showing
Compelling Impact on Multiple Measures of Myotonic
Dystrophy Type 1 (DM1); Dyne Plans to Initiate
Registrational Expansion Cohort to Support Potential
Submission for U.S. Accelerated Approval for DYNE-101
in DM1 in H1 2026 More
- Inozyme Pharma: Positive Interim Data for INZ-701 in
Infants and Young Children With ENPP1 Deficiency and
Key Program Updates More
- Invivyd: Continued Neutralizing Activity of PEMGARDA
(pemivibart) Against Dominant SARS-CoV-2 Variant XEC More
- Mersana Therapeutics: Additional FDA Fast Track
Designation Granted to Emiltatug Ledadotin (XMT-1660)
More
- Mersana Therapeutics: Positive Initial Clinical Data
From Phase 1 Clinical Trial of Emiltatug Ledadotin
(XMT-1660); Initiation of Expansion in Triple Negative
Breast Cancer More
- Monte Rosa Therapeutics: Corporate Update and Key
Anticipated Milestones for 2025 More
- Naveris: Expansion of the NavDx Test in Anal Cancer
Molecular Residual Disease Surveillance More
- Nirrin Technologies: Establishes Scientific Advisory
Board With Seasoned Leaders in Biomanufacturing and
Advanced Therapeutic Development More
- Orna Therapeutics: Appoints Vikas Sinha to Its Board
of Directors More
- Rapport Therapeutics: New Phase 1 Data, Further
Supporting RAP-219's Transformative Potential for CNS
Disorders More
- Revvity: FDA Clearance for First Automated Free
Testosterone Test More
- SpectraWAVE: Appoints Brad Davis as Chief
Commercial Officer and Bill Kelly as Chief Financial
Officer More
- Spero Therapeutics: Business Update and Announces
Interim Leadership Changes More
- Thermo Fisher Scientific: Olink Platform Selected
for World’s Largest Human Proteome Study More
- Vertex and Zai Lab: Strategic Agreement to Develop
and Commercialize Povetacicept in Mainland China, Hong
Kong SAR, Macau SAR, Taiwan Region and Singapore More
- Zai Lab: Strategic Partnership With MediLink
Therapeutics to Develop a Novel LRRC15 Antibody-Drug
Conjugate More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Amylyx Pharmaceuticals: Proposed Public Offering of
Common Stock More
- City Therapeutics: Strategic Collaboration With
Bausch + Lomb to Develop a Novel RNAi-Based
Treatment for Geographic Atrophy More
- etherna: Strategic Multi-Target Collaboration
With Dropshot Therapeutics More
More
- Harbour BioMed: License Agreement With Windward
Bio for HBM9378/SKB378, an Anti-TSLP Fully Human
Antibody for Immunological Diseases More
- Intellia Therapeutics: Anticipated 2025
Milestones and Strategic Reorganization to
Prioritize the Advancement of Its Late-Stage
Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
More
More
More*
- iTeos: 2025 Strategic Priorities and Anticipated
Milestones More
- Life Science Review of 2024: Analyzing
Developments and Planning for Future Success Video
- Mediar Therapeutics: Enters Into Global Licensing
Agreement With Lilly to Advance First-in-Class WISP1
Antibody for the Treatment of Idiopathic Pulmonary
Fibrosis (IPF) More
More
More*
- More on Climb Bio Ascending From Eliem Legacy With
$9M Upfront Deal for Preclinical IgA Antibody More
- More on Novo Nordisk, Valo Health Inking Expanded
Up-to-$4.6B AI Collaboration More
- Navigating JPM Week 2025: Overcoming Challenges
and Maximizing Value Video
- Repare Therapeutics: Portfolio Re-Prioritization,
Partnering Initiatives and Cost Reductions More
More
More*
- Rhythm Pharmaceuticals: Preliminary Fourth Quarter
and Full Year 2024 Net Product Revenues, Pipeline
Advancements and Upcoming Milestones More
- scPharmaceuticals: Preliminary Unaudited Fourth
Quarter and Full Year 2024 Financial Results More
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- Base Editing Addresses Inherited Macular
Degeneration in Primate, Human Tissue Models More
- Beyond Biotech: Developing Non-opioid Pain Drugs Podcast
- Broad: Scientists Engineer CRISPR Enzymes That Evade
the Immune System More
- Join Big4Bio CBO Dave Whelan in Munich for DxPx;
Save With a Special Discount Code! More
- Pharma Optimism Forecast for JP Morgan Healthcare
Conference More*
- Subscribe to LifeSci Startup for Updates on
US Startups More
- The
Massachusetts Biotech Industry Rebounded in 2024. Can
the Momentum Last? More*
- Wyss: From Data to Drugs: The Role of Artificial
Intelligence in Drug Discovery More
|
|
|
|
Section
Sponsor:
|
 |
|
|
| SECTION SPONSOR: |
 |
|
|
- Big4Bio:Boston Life Science Company
Directory More
|
NOTE:
EVENTS AND JOBS ARE FROM ALL BIG4BIO REGIONS
|
|
|
|
|
|
|
|
|
Section
Sponsor:
|
 |
|
|
|
|
- OPPORTUNITY: Senior Director, Integrated Marketing
& Communications - Remote More
- OPPORTUNITY: Clinical Development Leader - New York,
NY More
- OPPORTUNITY: Sales Executive - Hybrid More
- OPPORTUNITY: Senior Director of Business Development
- Remote More
- OPPORTUNITY: Vice President of North America Medical
Affairs - MA More
- OPPORTUNITY: Vice President of Sales &
Marketing, North America - Remote More
|
|
|
|
Section
Sponsor:
|
|
|
|
|
